HARVARD BIOSCIENCE INC 8-K

What Happened Harvard Bioscience, Inc. (HBIO) announced on January 23, 2026 that its Board approved "Project Viking," a plan to consolidate manufacturing operations. The plan closes the Holliston, MA production facility, shifts U.S. production to Minneapolis, MN, and relocates certain operations to facilities in Germany, Sweden, and the U.K. The company issued a press release about the program on January 29, 2026 (Regulation FD disclosure).

Key Details

• Approved by the Board: January 23, 2026; press release issued January 29, 2026.
• Expected pre-tax restructuring charges: approximately $3.4 million to $4.4 million.
• Estimated non-cash asset write-off / accelerated depreciation: ~$0.6 million to $0.7 million.
• Expected cost savings: about $3.0 million in 2027 and ~$4.0 million in annual savings beginning in 2028.
• Restructuring actions are expected to be substantially complete by the first half of 2027; additional charges possible if circumstances change.

Why It Matters This is a material operational restructuring aimed at reducing overhead, rationalizing SKUs, and improving manufacturing efficiency. For investors, the key takeaways are the near-term restructuring costs (estimated $3.4–$4.4M) and the planned multi-year run-rate savings (about $3M in 2027 and $4M annually from 2028). The closure and relocations could affect production timing, workforce, and short-term cash flow; the company notes estimates may change and additional charges could be incurred.